Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases-Reference-Cited by-同舟云学术

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Published:2018-03 Issue:3 Volume:29 Page:669-680
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Turner N.C.,Finn R.S.,Martin M.,Im S.-A.,DeMichele A.,Ettl J.,Diéras V.,Moulder S.,Lipatov O.,Colleoni M.,Cristofanilli M.,Lu D.R.,Mori A.,Giorgetti C.,Iyer S.,Bartlett C. Huang,Gelmon K.A.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/669/24530920/mdx797.pdf

Reference22 articles.

1. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options;Harb;Cancer Manag Res,2015

2. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology guideline;Rugo;JCO,2016

3. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Breast,2017

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 2.2017. https://www.nccn.org/store/login/login.aspx? ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (5 July 2017, date last accessed).

5. Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey;Lin;Cancer Med,2016

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16

2. Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)✰;Journal of the National Cancer Center;2023-12

3. Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors;Journal of Chemotherapy;2023-11-09

4. Reporting of older subgroups in registration breast cancer trials 2012–2021;Breast Cancer Research and Treatment;2023-09-04

5. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis;Breast Cancer Research and Treatment;2023-08-16